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Context: Patients with pheochromocytomas and paragangliomas (PGLs) may have brown adipose
tissue (BAT) activation induced by catecholamine excess. 18F-fluorodeoxyglucose (18F-FDG) posi-
tron emission tomography (PET)/computed tomography (CT) can be used for the localization of
both PGLs and BAT. It is unknown whether BAT is specifically affected by altered cellular energy
metabolism in patients with SDHx- and VHL-related PGLs.
Objective: The objective of the study was to determine endocrine and paracrine effects of cate-
cholamine excess on BAT activation in patients with PGLs as detected by 18F-FDG PET/CT, taking into
account genetic variation.
Design: Patients with PGLs who were fully genetically characterized underwent presurgical 18F-
FDG PET/CT imaging for tumor localization and to quantify BAT activation.
Setting: The study was conducted at a single Dutch tertiary referral center.
Patients and Intervention: Seventy-three patients, aged 52.4  15.4 years, with a body mass index
of 25.2  4.1 kg/m2, mean  SD, were grouped into sporadic, cluster 1 (SDHx, VHL) and cluster 2
(RET, NF1, MAX) mutations.
Main Outcome Measures: 18F-FDG mean standard uptake values were assessed in predefined BAT
locations, including perirenal fat.
Results: Twenty-one of 73 patients (28.8%) exhibited BAT activation. BAT activation was absent in
all six patients with nonsecreting PGLs. No difference in 18F-FDG uptake by perirenal fat on the side
of the pheochromocytoma and the contralateral side was observed (mean standard uptake value
of 0.80 vs 0.78, respectively, P  .42). The prevalence of BAT activation did not differ between
sporadic (28.9%), cluster 1 (40.0%), and cluster 2 patients (15.4%, P .36).
Conclusion: Patients with PGLs exhibit a high prevalence of BAT activation on 18F-FDG PET/CT. This
is likely due to systemic catecholamine excess. BAT activation is not associated with specific germ-
line mutations. (J Clin Endocrinol Metab 101: 224–232, 2016)
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Abbreviations: BAT, brown adipose tissue; BMI, body mass index; BRITE, brown in white; CT,
computedtomography;18F-FDG,18F-fluorodeoxyglucose;MAX,myc-associatedfactorX;PET,
positron emission tomography; PGL, paragangliomas; RET, rearranged during transfection;
SDH, succinate dehydrogenase; SUV, standard uptake value; TMEM, transmembrane protein;
UCP1, uncoupling protein-1; VHL, von Hippel-Lindau; VOI, volume of interest.
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Brown adipose tissue (BAT) is present in infants anddiminishes with age (1). Activation of BAT can be
visualized using in vivo imaging with 18F-fluorodeoxyg-
lucose (18F-FDG) positron emission tomography (PET)/
computed tomography (CT) imaging and has led to the
realization that remnants are still present in adulthood (2,
3). The role of BAT in metabolism and obesity has led to
greater interest in the regulatory mechanisms of this tissue
(4). It has been shown in animal studies that norepineph-
rine stimulation of BAT via 3-receptors lead to increased
number of brown fat cells, lipolysis, glucose transporta-
tion, expression of uncoupling protein-1 (UCP1), and ul-
timately heat production (5). In humans, systemic cat-
echolamines may similarly play a role in stimulation of
BAT.
Hypersecretion of catecholamines is the hallmark of
pheochromocytomas and sympathetic paragangliomas
(PGLs). PGLs are neuroendocrine tumors of the adrenal
medulla and sympathetic paraganglia. In vivo cancer im-
aging with 18F-FDG PET/CT uses the characteristic of in-
creased uptake of glucose and 18F-FDG by tumor cells,
relative to normal cells. In patients with PGLs, activated
BAT tissue is often visualized (6, 7), and it was present in
up to 27% of patients when various functional imaging
studies, including 18F-FDG PET/CT, were combined (8).
The recruitment of BAT appears to be dynamic, with case
reports of patients with PGLs demonstrating BAT activa-
tion in association with increased systemic catecholamine
levels, whereas normalization of catecholamines after sur-
gery subsequently led to a significant reduction of BAT
activation (9, 10).
The classical depot of BAT is located interscapularly. In
animal studies, chronic cold stimulation or  -adrenergic
stimulation leads to brown adipocytes dispersed in white
adipose tissue, which have been termed inducible brown
adipocytes, brown in white (BRITE) or beige adipocytes.
Whereas classical BAT cells are derived from a myf-5 cel-
lular lineage (similar to skeletal muscle cells), beige adi-
pocytes are derived from a myf-5-negative lineage (similar
to white fat) (11). Recent studies on the BAT depots in the
supraclavicular area in adults found predominantly
BRITE adipocytes, with only some overlap with the clas-
sical BAT, demonstrating that it cannot be differentiated
by anatomical location (12). Recently this coexistence of
BRITE and classical BAT was found in the peritumoral fat
surrounding a pheochromocytoma, whereas BAT was ab-
sent around nonfunctional adrenal adenomas, leading to
suggestions that local catecholamines had a paracrine ef-
fect on the browning of peritumoral fat (13). Because the
kidneys and the adrenal glands are encapsulated by a com-
mon connective tissue (Gerota’s fascia), we hypothesized
that local catecholamine secretion and action from the
PGLs might lead to an increased BAT activation in the
adjacent perirenal fat.
Up to 40% of PGLs are caused by germline mutations
in tumor susceptibility genes, including von Hippel-
Lindau (VHL), succinate dehydrogenase subunits A, B, C,
and D, and assembly factor 2 (SDHA/B/C/D/AF2), neu-
rofibromatosis type 1 (NF1), rearranged during transfec-
tion (RET), myc-associated factor X (MAX) and trans-
membrane protein (TMEM127) (14). Based on gene
expression profiling, PGLs can be classified into cluster 1
(VHL, SDHx) with increased expression of genes associ-
ated with angiogenesis and hypoxia, and cluster 2 (RET,
NF1, MAX, TMEM127) with increased expression of
genes associated with RNA synthesis and kinase signaling
(15, 16).
SDHx mutations cause impairment of succinate dehy-
drogenase (SDH) function in the mitochondria electron
transport chain and hence compromise oxidative phos-
phorylation (16–18). Similarly, VHL-related PGLs mu-
tations also have impaired oxidative phosphorylation
(19). This results in activation of the hypoxic-angiogenic
pathway via transcription factors hypoxia-inducible fac-
tors (types 1 and 2) (20). Their main target genes in-
clude genes involved in glucose metabolism such as glu-
cose transporters, hexokinases, and angiogenesis
(vascular endothelial growth factor) as well as survival
and motility (21). 18F-FDG uptake varies among PGLs of
different genotypes, with the highest standard uptake val-
ues (SUVs) observed in PGLs belonging to cluster 1 (22).
Because these are germline mutations, there is potential to
affect all cells with mitochondria, including BAT, which
contains abundant mitochondria.
The aims of this study were to determine the systemic
and paracrine effects of excess catecholamine secretion by
PGLs on BAT and to determine whether specific germline




Seventy-three consecutive patients (aged 52.4  15.4 y, body
mass index (BMI) 25.2  4.1 kg/m2, mean  SD, 40 men and 33
women) with a confirmed PGL who had undergone an 18F-FDG
PET/CT scan between December 2007 and February 2015 were
studied. Sixty tumors (82.2%) were adrenal, two (2.7%) extraa-
drenal, and 11 (15.1%) metastatic PGLs. Seventy-two patients
had histological confirmation of a PGL, whereas one patient had
metastatic PGL as proven by extreme elevations of metaneph-
rines and typical imaging features. Collection of plasma meta-
nephrines were collected under strict clinical protocol (23), and
they were measured using liquid chromatography with electro-
chemical detection (24). All patients had undergone genetic test-
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ing for germline mutations in known susceptibility genes. Forty-
five patients had sporadic tumors, 15 patients belonged in cluster
1 (SDHA, n  2; SDHB, n  5, SDHD, n  7, VHL, n  1), and
13 patients belonged to cluster 2 (RET, n  8; NF1, n  4; MAX,
n  1). Six patients had nonfunctional PGLs (with consistently
normal plasma metanephrines levels), of whom one was spo-
radic, and the remaining five belonged to cluster 1 (SDHB, n 
2; SDHD, n  3) (Table 1). Data were collected under conditions
of regular clinical care, with the approval of ethics committee
obtained for the retrospective use of those data, for scientific
purposes. All patients consented in the use of their clinical data.
Imaging procedures
Our 18F-FDG PET/CT scanning protocol has been previously
described (25). After the injection of 18F-FDG, patients sat for 60
minutes in a quiet room in which the ambient temperature was
set at 20ºC. Subjects were neither warmed nor instructed to avoid
cold before the PET/CT examinations. Data on age, sex, height,
weight, fasting plasma glucose level, and use of -blockers and
-blockers were obtained for all patients. Outdoor temperatures
were registered to account for seasonal differences based on data
from the Royal Netherlands Meteorological Institution.
Image interpretation and quantitative
measurements
18F-FDG PET/CT images were reviewed using Inveon Re-
search Workplace software (version 4.1; Siemens Healthcare).
Both the researcher (T.P.) and a nuclear medicine physician
(B.B.) interpreted the images. Classical sites of BAT activation
were assessed, which included cervical, supraclavicular, axillary,
mediastinal, pericardial, periaortal, and perirenal tissue. BAT
activation was deemed present if there was increased uptake of
18F-FDG, identified by a maximum standardized uptake value
(SUVmax) greater than 1.5 on PET (approximately 6 times higher
than in white adipose tissue), and it corresponded to an area of
fat on CT (Hounsfield units: 10 to 180) (26). A volume of
interest (VOI) was then drawn up in the area of maximal uptake
(Figure 1), with a fixed cubic size of 8  8  8 mm (total volume
1.014 mm3) and used for quantitative analysis.
Regardless of the presence of BAT activation, VOIs were also
drawn in several sites in all patients: bilateral supraclavicular fat
(representing typical BAT site), sc abdominal fat (representing
typical white adipose tissue site), and bilateral perirenal fat (rep-
resenting possible site of BRITE fat). In the perirenal fat, VOIs
were drawn up bilaterally at three levels: upper third, middle
third, and lower third relative to the kidneys. The average of the
three levels was then taken for each side. In patients with peri-
renal fat volume that was less than the VOI (8  8  8 mm), this
could not be assessed. Maximum and mean standardized uptake
values (SUVmax and SUVmean) were established in all VOIs. SU-
Vmax of tumors were also measured as previously described (25).
They were normalized for body weight and were calculated as
SUV  A/IA  BW (A, activity concentration of VOI [bequerels
per milliliter]; BS, body weight [grams]; IA, injected activity [be-
querels]). All calculated SUVs were decay corrected using the
following formula: A0  At  e
t (A0, corrected activity; At,
uncorrected activity; , decay constant [In2/11] minutes1; t,
elapsed time in minutes).
Statistical analysis
Baseline characteristics were presented in mean  SD for con-
tinuous variables and number (percentage) for categorical vari-
ables. Kruskal-Wallis test with post hoc Dunn test for continuous
variables and Fisher’s exact test for categorical variables were
used to compare the baseline characteristics between the muta-
tion groups. Wilcoxon rank-sum test and Fisher’s exact tests
were used to compare between BAT patients and non-BAT pa-
tients to assess for risk factors for BAT activation.








(n  73) P
Age, y 56.0  13.9 44.2  16.8 49.7  15.8 52.4  15.4 .03d
Sex, females, % 21 (46.7) 7 (46.7) 5 (38.5) 33 (45.2) .89
BMI, kg/m2 25.2  4.3 25.5  4.1 24.7  3.6 25.2  4.1 .96
-Blocker use, % 16 (35.6) 3 (20.0) 2 (15.4) 21 (28.8) .33
-Blocker use, % 31 (68.9) 7 (46.7) 7 (53.8) 45 (61.6) .25
Diabetes mellitus, % 8 (17.8) 1 (6.7) 1 (7.7) 10 (13.7) .56
Tumor location, A/E/M 40/0/5 7/2/6 13/0/0 60/2/11
Plasma normetanephrine, 48–495 pmol/L 10 028  16 123 8419  14 347 3477  5666 8532  14 500 .17
Plasma metanephrine, 57–295 pmol/L 2658  3313 195  92 1540  2166 1953  2912 .001e
Nonfunctional, % 1 (2.2) 5 (33.3) 0 (0.0) 6 (8.2) .001
Abbreviations: A, adrenal; E, extraadrenal; M, metastatic disease. Results are presented as mean  SD unless stated. P value shown in the last
column are from a Kruskal-Wallis test for comparing the three groups if the variable is continuous and Fisher’s exact test if the variable is
categorical.
a Patients were tested for the presence of germline mutations and large deletions in SDHB/C/D, RET, VHL, and since 2011, in SDHA, SDHAF2,
TMEM 127, and MAX.
b Patients with germline mutations in succinate dehydrogenase subunits A, B, C, and D and assembly factor 2 (SDHA/B/C/D/AF2), and von Hippel-
Lindau (VHL).
c Patients with germline mutations in neurofibromatosis type 1 (NF1), rearranged during transfection (RET), myc-associated factor X (MAX), and
transmembrane protein (TMEM127).
d P  .02 between cluster 1 and sporadic.
e P  .001 between cluster 1 and sporadic, P  .003 between cluster 1 and cluster 2.
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In patients with a functioning unilateral tumor, we assessed
for a paracrine effect of a tumor stimulating BAT activation in
the surrounding fat, by comparing the average perirenal VOIs
ipsilateral to the tumor with the contralateral side, using a Wil-
coxon matched-pairs signed-ranks test.
For comparison of SUVs of different genotypes, the SUVmean
(supraclavicular), SUVmean (abdominal fat), and SUVmean (peri-
renal fat) were analyzed using Kruskal-Wallis test with the post
hoc Dunn test along with SUVmax (tumor) and SUVmax (of the
most active BAT site). The presence of BAT activity was analyzed
in the functional and nonfunctional groups and the genotype
clusters, using Fisher’s exact test. All statistical computations
were performed with STATA version 12.1 (StataCorp LP). Fig-
ures were produced with GraphPad Prism version 5.0 for Win-
dows (GraphPad Software). All tests will be two tailed with sig-
nificance set at P  .05.
Results
Systemic catecholamines and BAT activation
Overall, 21 of 73 patients (28.8%) had BAT activation
(Supplemental Table 1). Twenty-one of 67 functional tu-
mors (31.3%) had BAT activation, compared with none of
the six patients with nonfunctioning tumors (P  .17).
Patients with BAT activation were significantly younger
when compared with patients without BAT activation
(age 41.4  14.6 y vs 56.9  13.5 y [P  .001]), whereas
there was a trend towards a lower BMI and lower outdoor
temperature (Table 2). However, levels of normetaneph-
rine and metanephrine, the metabolites of norepinephrine
and epinephrine, respectively, did not significantly differ
between both groups (11974  17 125 pmol/L vs 7140 
13 227 pmol/L, P  .24, and 1778  3471 pmol/L vs
2024  2688 pmol/L, P  .19). A total of 28.8% of pa-
tients were using -blockers at the time of the scan, and
there was no difference between those with and without
BAT activation. In a subgroup analysis looking only at
patients without prior -blockers use, there was a trend
toward patients with BAT activation having a higher
plasma normetanephrine level compared with those with-
out activation, although this did not reach statistical sig-
nificance (9801  15 434 pmol/L and 3362  4481
pmol/L, P  .09).
Figure 1. A 55-year-old man with left sporadic pheochromocytoma and BAT activation. A and B, Coronal PET/CT fusion (A) and coronal CT (B)
images show increased uptake of 18F-FDG activity mapped to areas of fat density among neck (thin white arrow) and mediastinum (thick white
arrow). Uptake is greater in contralateral (right) perirenal fat (blue arrows) compared with the ipsilateral (left) side surrounding the tumor (*). C
and D, Transversal PET/CT fusion (C) and CT (D) images show mildly increased uptake of 18F-FDG activity in bilateral supraclavicular areas, with
VOIs drawn (white boxes). E and F, Transversal PET/CT fusion (E) and CT (F) images show increased uptake of 18F-FDG activity in perirenal areas
(blue arrows), with activity greater on the contralateral side of the tumor (*). G, Transversal PET/CT fusion images showing VOIs of perirenal fat
(white arrows) and sc fat (blue arrows) (I). H and I, Transversal PET/CT fusion (H) and CT (I) images show BAT activation in periaortal (white arrow)
and perivertebral (blue arrow) sites.
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The supraclavicular area was the most frequent site in
which BAT activation was found, in 18 of the 21 patients
(85.7%) with BAT activation. The next most common
sites were neck, mediastinum, and perivertebral areas,
with detection in 14 patients (66.7%), whereas perirenal
activation was noted in six patients (28.6%).
Paracrine effects of catecholamines on BAT
Among the 73 patients, we excluded 18 patients with
inadequate perirenal fat for assessment, six with nonfunc-
tional tumors and five with bilateral or nonadrenal tu-
mors.The remaining44patientshadunilateral, functional
pheochromocytomas and were assessed for BAT activa-
tion of perirenal fat as a reflection of paracrine effects of
locally released catecholamines. The mean ipsilateral peri-
renal SUVmean did not significantly differ from the con-
tralateral side (0.78  0.77 vs 0.80  0.86, P  .32).
Twenty-five patients had a higher SUVmean on the con-
tralateral side, compared with 19 patients with higher SU-
Vmean on the ipsilateral side (Figure 2).
BAT activation across different genotypes
BAT activation was observed in 13 of 45 patients with
sporadic tumors (28.9%), 6 of 15 in cluster 1 patients
(40.0%), and 2 of 13 in cluster 2 patients (15.4%, P 
.36). The mean SUVmax of the tumors in cluster 1 was
significantly higher than both sporadic and cluster 2 tu-
mors (18.5  9.2 vs 5.8  4.6 and 3.8  1.5, P  .001)
(Figure 3). However, no statistical difference was found in
the SUVmax of the most active BAT site between these
groups (3.7  5.7 vs 1.6  2.2 vs 1.5  2.9, respectively,
P  .26). Similarly, in the supraclavicular, sc, and perire-
nal sites, SUVmean was similar in all groups (Figure 3).
Between the mutation groups, there was no significant
difference in the number of BAT sites that were noted
among patients with BAT activation (4.5  1.9 vs 6.2 
2.1 vs 5.0  2.8, P  .26).
Discussion
This is the first study to date of fully genetically charac-
terized patients with PGLs, looking to examine the effects
of genotype differences on the activation of brown fat
using 18F-FDG PET/CT imaging. Although significantly
higher FDG uptake was detected in tumors of patients
with cluster 1 mutations compared with those with cluster




(n  52) P
Age, y 41.4  14.6 56.9  13.5 .001
Sex, females, % 10 (47.6) 23 (44.2) .80
BMI, kg/m2 24.0  3.6 25.7  4.3 .06
-Blocker use, % 5 (23.8) 16 (30.8) .78
-Blocker use, % 13 (61.9) 32 (61.5) 1.00
Diabetes mellitus, % 2 (9.5) 8 (15.4) .71
Outdoor T, ºC 7.6  7.9 10.5  6.3 .14
Serum glucose, mmol/L 5.8  1.2 6.0  1.3 .72
Plasma normetanephrine, 48–495 pmol/L 11 974  17 125 7140  13 227 .24
Plasma metanephrine, 57–295 pmol/L 1778  3471 2024  2688 .19
Abbreviation: T, temperature. Results presented as mean  SD unless otherwise stated. The P values shown in the last column are from a
Wilcoxon rank-sum test for comparing the two groups if the variable is continuous and Fisher’s exact test if the variable is categorical.
Figure 2. Comparing SUVmean of perirenal fat on ipsilateral side of
pheochromocytoma to contralateral perirenal fat in 44 patients with a
functional unilateral pheochromocytoma.
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2 mutations or sporadic, there was no difference in BAT
activity between the groups in terms of BAT prevalence
and 18F-FDG uptake at various BAT sites. Local release of
catecholamines from a tumor do not appear to lead to
increased BAT activation in the adjacent perirenal fat be-
cause the activity on the ipsilateral side was not greater
than the contralateral side. At the same time, we confirmed
a high proportion of patients with PGLs (28.8%) with
BAT activation, which is much higher than the prevalence
of 3%–7% reported in general adult population studies
(27). BAT activation was not present in patients with non-
functional tumors.
Systemic effects of catecholamines
In a previous large study by Hadi et al (8) in patients
with PGLs, BAT activation was noted on 18F-FDG
PET/CT in a similar proportion of patients with confirmed
PGLs (13 of 59, 22%). They found a mean SUVmax of the
BAT tissue of 3.9, similar to ours of 4.0, which is well
above the PET activity of normal fat. Age is often consid-
ered the strongest determinant for BAT activation (28),
and this was confirmed by our study. There was a trend
toward colder outdoor temperature and lower BMI in-
creasing BAT activation, which are well described factors
(29)
BAT activation was detected only in patients with func-
tional tumors and in none of the patients with nonfunc-
tional tumors. This is similar to a previous study showing
BAT activation only in patients with functional PGLs but
not in 20 patients or subjects with normal metanephrines
levels (30). This supports the role of systemic cat-
echolamines in BAT activation. Hadi et al (8) found higher
mean norepinephrine levels in BAT activation. We could
not confirm an association between normetanephrine lev-
els and BAT activation. There could be several explana-
tions for this, such as the use of -blockers by patients in
the current study. Also, down-regulation of catechol-
amine receptors has been known to occur in patients with
functional PGLs, limiting the effects of catecholamine ex-
cess, and this may occur similarly in BAT (31).
Local effects of catecholamines
Local effects of catecholamines may be relevant be-
cause a recent study demonstrated induction of brown fat
around a pheochromocytoma, suggesting that the local
catecholamine release from the tumor may stimulate local
Figure 3. Median ( interquartile range) uptake of 18F-FDG in various tissues in patients with sporadic PGLs, cluster 1 (SDHA, SDHB, SDHD, VHL)
and cluster 2 (RET, NF1, MAX) mutations. A, SUVmax of tumor. *, SUVmax greater in cluster 1 compared with sporadic tumors (P  .001). B, Total
number of sites with BAT activation (areas assessed were cervical, supraclavicular, axillary, mediastinal, pericardial, periaortal, and perirenal). C,
SUVmean at supraclavicular area (classical BAT site). D, SUVmean at perirenal fat (possible brown to white adipose site). E, SUVmean at sc fat (white
adipose tissue).
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depots of adipose tissue (13). Humans, similar to rodents,
have two types of brown adipocytes, classical and BRITE
(11). Using cell-specific markers, both classical and BRITE
BAT in the adipose tissue surrounding the tumor were iden-
tified. This coexistence of both brown adipocytes has also
been shown in supraclavicular fat (12) and highlights the
difficulty indifferentiating the twodepots,usingcellmarkers
with currently undefined cell functions (32). The importance
of distinction between the two types is that they may be stim-
ulated and recruited by different signals (4).
This finding led us to look for evidence of perirenal fat
being stimulated by the local catecholamines released
from an adjacent pheochromocytoma. Nevertheless, there
was no difference between the SUVmean of the perirenal fat
on the ipsilateral side of the tumor compared with the
contralateral side. A plausible explanation would be that
some of these pheochromocytomas have only mild cate-
cholamine excess. On the other hand, even in a subgroup
of patients with at least 10 times the elevation of plasma
normetanephrines (n  16), the findings were similar,
with mean SUVmean of the ipsilateral perirenal fat not
greater than the contralateral side (1.12  1.13 vs 1.19 
1.27, P  .28).
Of the 21 patients with BAT activation, six (28.6%)
demonstrated perirenal BAT activation, similar to another
study that had a prevalence of 26.3% (29). In these six
patients, the perirenal site was the site of greatest BAT
activity (highest SUVmax) in two patients, of whom one
patient had a metastatic bladder paraganglioma, and high
perirenal BAT activation could not be attributed to local
hormonal release.
It is still possible that perirenal BAT activation is often
present around a pheochromocytoma, as previously sug-
gested (13), because PET may underestimate BAT activity
(33). Tissue measurements of UCP1, a specific marker for
brown adipocytes, can detect smaller quantities of BAT
and probably is more sensitive (5). However, PET is able
to reflect the quantity of BAT tissue, and only one of these
six patients with perirenal BAT had increased activity of
perirenal fat on the ipsilateral side of the tumor. It is also
worthwhile to note that in addition to paracrine effects of
a tumor, if any, all patients were also exposed to the sys-
temic effects of catecholamine excess, and this study was
not able to distinguish the effects of the two. Taken to-
gether, we could not confirm previous suggestions of the
browning of perirenal fat from paracrine effects of a
pheochromocytoma.
Germline mitochondrial mutations and BAT
activity
SDH genes are nuclear genes encoding for mitochon-
drial proteins, and they act as tumor suppressors. In PGL
tumors, SDHx mutations result in defects in the mito-
chondrial oxidation pathway, accumulation of succinate,
stabilization of the hypoxia-inducible factor pathway, and
tumorigenesis via the Warburg effect (34). Although this
is a germline mutation, patients with SDHx mutations do
not appear to exhibit increased propensity to tumors in
other tissues, leading to the hypothesis that a second hit is
required (35). The sympathetic ganglia and adrenal me-
dulla appear to be more vulnerable to tumor development,
possibly due to their oxygen sensing properties. BAT,
which contains abundant mitochondria, offers a possibil-
ity to examine for altered energy metabolism in nontu-
moral tissue of patients with PGLs and germline
mutations.
18F-FDG uptake was greater in cluster 1 tumors, con-
sistent with prior findings, and we previously identified
that this is due to accelerated glucose phosphorylation by
hexokinases and not increased glucose transporter expres-
sion (25). In contrast, there was no significant difference
between the mutation groups, in terms of prevalence of
BAT activation, number of sites, or intensity of BAT (SU-
Vmax). Furthermore, in predefined VOIs of the supracla-
vicular, perirenal, and sc fat, there was no significant dif-
ference in SUVmean in the different clusters. Patients with
cluster 1 mutations were younger than patients with spo-
radic tumors, which is expected because it is an inherited
condition. Despite this, there was still no increase in prev-
alence of BAT activation in patients with cluster 1
mutations.
One possible explanation is that although there is loss
of heterozygosity in SDHx-related PGLs, germline muta-
tions are present in only one allele in nontumoral cells and
might therefore not affect mitochondrial function. This
might explain lack of BAT activation. Another possibility
is that 18F-FDG PET/CT visualizes only glucose uptake
and not free fatty acids, which is a major substrate of BAT
(36). A third possible explanation is that UCP1 in BAT
uncouples the normal respiratory chain by using the pro-
ton gradient across the mitochondrial membrane to gen-
erate heat instead of ATP production. Although we expect
that SDH functional loss may lead to induction of hypoxic
pathways and increased glucose consumption, it is also
possible, that because UCP1 generates heat from the pro-
ton gradient, SDHx mutations that lead to impairment of
mitochondrial complex II, as evidenced by lower complex
II activity and lower ATP/ADP/AMP content (18), may
reduce the proton gradient generated and hence lead to
lower BAT activity.
There are several limitations in this study. Being a ret-
rospective study, we did not control for confounders such
as outdoor temperature or medication use. However,
scanning condition was standardized and we collected in-
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formation with regard to these possible confounders. Use
of -blockers may reduce BAT activation (37). However,
this should lower only the prevalence or activity of BAT
detected on PET and lead to an underestimation, whereas
we found a high prevalence of BAT activation. Also,
-blocker use was equally distributed among the genetic
mutation groups. Using a single VOI to measure the SU-
Vmean or SUVmax of various sites of BAT activation may
underestimate the true volume of BAT tissue in that par-
ticular site. However, there is currently no agreed univer-
sal method to quantify BAT activity on PET (26). Hence,
we ensured that we consistently used the same standard-
ized method among all patients. We acknowledge that no
control population was available, but our main focus was
to study paracrine and genetic effects.
Conclusion
Significant BAT activation can be detected in up to 30%
of patients with PGLs. This is likely to be due to systemic
effects of catecholamine excess. We could not confirm a
paracrine effect of catecholamine secretion by pheochro-
mocytomas on perirenal BAT activation. However, 18F-
FDG PET/CT might not be the most sensitive tool to detect
such an effect, and paracrine effects may be superseded by
systemic catecholamine effects. Furthermore, germline
SDHx mutations appear to play no role in systemic BAT
activation, although this awaits further investigations on
a molecular level.
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